ArticleScientific reports2017
The G6PD flow-cytometric assay is a reliable tool for diagnosis of G6PD deficiency in women and anaemic subjects.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- Trial
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with elevated mean corpuscular volume (MCV) and bilirubin.BMC genomic data · 2026Article
- Tafenoquine lactation pharmacokinetics: a pilot study.Malaria journal · 2025Article
- Optimizing Testing Time for Methaemoglobin Reduction Test in G6PD Screening: A Comparative Study of Monica Cheesbrough's Protocol and a Modified Approach at a Hospital in a Resource-Restraint Country, Ghana.Advances in hematology · 2025Article
- Unexpected Rasburicase-Induced Hemolysis in a Patient With Normal Glucose-6-Phosphate Dehydrogenase Activity.Journal of medical cases · 2024Article
- Single-Drop Blood Detection of CommonACS omega · 2023Article
- Cancer Cell Culture: The Basics and Two-Dimensional Cultures.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria.Hematology (Amsterdam, Netherlands) · 2022Article
- Genotype-phenotype association and biochemical analyses of glucose-6-phosphate dehydrogenase variants: Implications for the hemolytic risk of using 8-aminoquinolines for radical cure.Frontiers in pharmacology · 2022Article
- Erythrocyte tropism of malarial parasites: The reticulocyte appeal.Frontiers in microbiology · 2022Review
- Reference spectrophotometric values for glucose-6-phosphate dehydrogenase activity in two-to six-month-old infants on the Thailand-Myanmar border.Wellcome open research · 2022Article
- Combined effects of double mutations on catalytic activity and structural stability contribute to clinical manifestations of glucose-6-phosphate dehydrogenase deficiency.Scientific reports · 2021Article
- Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa.Parasites & vectors · 2021Article
- Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study).PLoS neglected tropical diseases · 2021Article
- G6PD Variants and Haemolytic Sensitivity to Primaquine and Other Drugs.Frontiers in pharmacology · 2021Review
- Optimizing G6PD testing forWellcome open research · 2020Review
- Tafenoquine and G6PD: a primer for clinicians.Journal of travel medicine · 2019Review
- Bead-based assays to simultaneously detect multiple human inherited blood disorders associated with malaria.Malaria journal · 2019Article
- Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities.International health · 2019Article
- Clinical utility of tafenoquine in the prevention of relapse ofInfection and drug resistance · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucose-6-phosphate dehydrogenase (G6PD) activity is essential for redox equilibrium of red blood cells (RBCs) and, when compromised, the RBCs are more susceptible to haemolysis. 8-aminoquinolines (primaquine and tafenoquine) are used for the radical curative treatment of Plasmodium vivax malaria and can cause haemolysis in G6PD deficient subjects. Haemolytic risk is dependent on treatment dose and patient G6PD status but ultimately it correlates with the number of G6PD deficient RBCs. The G6PD spectrophotometric assay reliably identifies deficient subjects but is less reliable in heterozygous females, especially when other blood conditions are present. In this work we analysed samples with a range of G6PD phenotypes and haematologic conditions from 243 healthy volunteers of Asian or African-American heritage using both the spectrophotomeric assay and the G6PD flow-cytometric assay. Overall 18.5% of subjects (29.3% of Asian females) presented with anaemia, associated with decreased RBCs volume (MCV) and reticulocytosis; the flow-cytometric assay showed good correlation with the spectrophotometric assay (Pearson's r 0.918-0.957) and was less influenced by haemoglobin concentration, number of RBCs and number of reticulocytes. This resulted in more precise quantification of the number of G6PD deficient RBCs and presumably higher predictive power of drug induced haemolytic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.